# Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects

> **NCT03007810** · PHASE1 · COMPLETED · sponsor: **Tianjin Hemay Bio-Tech Co., Ltd** · enrollment: 68 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Hemay005
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03007810
- **Lead sponsor:** Tianjin Hemay Bio-Tech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03007810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03007810, "Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03007810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*